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ABSTRACT
Objective: Hyperemesis gravidarum (HG) affects 0.3–3% of pregnant women and is a leading
cause of hospitalization in early pregnancy. The aim of the study was to investigate women’s
treatment and management of HG, as well as the consequences of HG on women’s daily life.
Design and setting: A cross-sectional study based on a structured telephone interview and an
online questionnaire. Participants were recruited by social media and by the Norwegian patient’s
organization for HG.
Subjects: Norwegian women that experienced HG.
Main outcome measure: Women’s perspectives on management and consequences of HG.
Results: The study included 107 women. Maternal morbidity was profound; about 3/4 of partici-
pants were hospitalized due to HG, and the majority showed clinical signs of dehydration (79%),
ketonuria (75%), and >5% weight loss (84%). Antiemetics were used by >90% and frequently
prescribed “as needed”. Metoclopramide (71%) and meclozine (51%) were most commonly
used. Participants described HG as having severe psychosocial consequences and profound
impact on daily activities. Almost two out of five reported thoughts of elective abortion, and 8
women had at least one elective pregnancy termination due to HG. Overall, 20 women (19%)
changed GPs due to dissatisfaction with HG management.
Conclusion: Despite the high psychosocial burden and major impact on daily activities, many
women with HG reported a lack of support from healthcare professionals and suboptimal man-
agement. Greater awareness and knowledge among healthcare professionals is needed to
improve care for women with HG.
KEY POINTS
There is a paucity of studies on management and the consequences of HG on women’s daily
lives and psychosocial burden. We found that:
 Many women described HG as one of their worst life experiences with profound morbidity.
 Many women reported suboptimal management of HG and lack of support from healthcare
professionals.
 Greater understanding of patient perspectives among healthcare professionals is important to
improve care and management for HG patients.
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Hyperemesis gravidarum (HG) is considered the most
severe manifestation of nausea and vomiting in preg-
nancy (NVP) and occurs in 0.3–3% of all pregnancies
[1,2]. HG causes weight loss, dehydration, electrolyte
disturbances, and nutritional deficiency. HG has also
been associated with premature delivery and small-
for-gestational-age infants [3]. Despite an apparently
relatively low incidence, the condition is the most
common cause of early pregnancy hospital admissions
[4]. Moreover, recurrence in consecutive pregnancies is
high, ranging from 15% to over 80% [5,6].
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Despite the severity of HG, there is no universal
consensus on the definition of the condition.
Therefore, HG is a clinical diagnosis without uniform
criteria [7,8]. Common criteria for diagnosis are persist-
ent vomiting accompanied by weight loss exceeding
5% of pre-pregnancy body weight, ketonuria, and
dehydration, which in many cases, requires intraven-
ous rehydration. The aetiology of HG is not clearly
understood, but it is thought to be multifactorial and
complex [7,9]. Recent studies have also suggested that
some women are more at risk due to genetic factors
[7]. Because there is no clear aetiology for HG, treat-
ment focuses on reducing the severity of symptoms
and preventing further complications such as electro-
lyte disturbances and malnutrition. First generation
antihistamines are considered safe and the first-line
antiemetic treatment. Dopamine receptor antagonists,
like metoclopramide and phenothiazines, are consid-
ered second-line drug therapies. Ondansetron is used
after other antiemetic medicines have failed [10–12].
In several countries, a combination of doxylamine and
vitamin B6 (pyridoxine) has been licensed for treating
NVP [13–15]. However, no medicines have been
licensed for treating NVP or HG in Scandinavia.
Most research related to NVP and HG has focused
on aetiology and treatment options, rather than the
patients’ experiences of HG management and conse-
quences. However, several studies have documented
that NVP and HG can have a profound negative
impact on women’s daily life functions; it negatively
affects the quality of life, daily activities, social func-
tions, work capacities/abilities, partner and family rela-
tionships, and parenting [16–20]. A recent systematic
review and meta-analysis also found that women with
HG ran significantly elevated risks of depression and
anxiety [21]. The condition can be so debilitating and
impose so much distress that women with severe NVP
and HG have considered or chosen to terminate an
otherwise wanted pregnancy [22,23]. In a web-based
survey of 808 women affected by HG, 15% of respond-
ents reported terminating at least one pregnancy, due
to HG [23]. In the same survey, 37% of respondents
reported that they would not consider or plan any
more pregnancies, which further illustrated the nega-
tive effect of HG on reproduction [20]. Christodoulou-
Smith et al. performed an online survey that included
377 women with HG and 233 controls. They found
that as many as 18% of women with HG fulfilled the
criteria of posttraumatic stress syndrome [24]. In that
study, women with HG were also more likely to have
experienced negative postpartum life events, including
financial, marital, career, and psychiatric problems,
compared to the control group of women [24].
The perception that NVP is a natural part of preg-
nancy, which poses only minor discomfort, may imply
that the symptoms are trivialized, both by healthcare
professionals and the public. This perception could
lead to lack of support, under-diagnosis, and under-
treatment of women with severe NVP. There is a pau-
city of studies on management and the consequences
of HG on women’s daily lives and psychosocial bur-
den. Moreover, to the best of our knowledge, no
study has investigated women’s experiences of HG in
a Scandinavian country using a structured interview to
capture women’s management of HG and impact on
daily life and functioning. The main objective of this
study was to investigate patients’ pharmacological
treatment and management of HG. We also aimed to
gain knowledge about the consequences of HG. These
results may be of great relevance for general practi-
tioners and all other healthcare professionals who
encounter pregnant women in antenatal care.
Material and methods
Design, recruitment and data collection
This study had a cross-sectional design. Data was col-
lected through a structured telephone interview and a
structured online questionnaire. The interview guide
and online questionnaire were developed based on
results from previous studies [17,20,25] and in collab-
oration with the Norwegian patients’s organization
for HG.
Due to the relative rarity of the disease, limited
inclusion criteria were applied. All women (age  18
years) that had experienced HG during their current or
former pregnancy were invited to participate in the
study. An invitation to participate in the study was
posted on several social media platforms including a
study Facebook page between mid-January and the
end of February 2015. Information about the study
was also disseminated by the Norwegian patient’s
organization for HG to its members. All women that
had signed an electronic declaration of consent and
provided contact information were contacted and
invited to participate in a telephone interview.
The interview included both closed-ended and
open-ended questions to capture women’s experien-
ces and perceptions, and the online questionnaire
included closed-ended questions with multiple choice
and ranking. The main topics in the interview and
online questionnaire were: (i) HG symptoms and sever-
ity, (ii) pharmacological treatment and management of
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE 31
HG, and (iii) psychosocial consequences and impact on
daily activities. To limit the duration of the telephone
interviews, questions more suitable for self-completion
were delivered in a self-administrated online question-
naire (www.questback.com).
The structured telephone interview was conducted
by a specially trained pharmacist/nurse. Participants
with more than one HG pregnancy were instructed to
select a specific HG pregnancy that they thought would
be most interesting to healthcare professionals that
care for patients with HG (hereby referred to as the
selected pregnancy). The women were asked to
respond to questions with the selected HG pregnancy
in mind.
Diagnostic criteria of HG
HG was defined as either a medical diagnosis of HG or
at least two out of three clinical features of HG: (1)
weight loss exceeding 5% of the pre-pregnancy
weight; and/or (2) ketones on a urine analysis; and/or
(3) dehydration and/or an electrolyte imbalance. We
excluded women who did not fulfill these diagnostic
criteria and women who had experienced HG more
than 2 years prior to the study.
Measures
Maternal characteristics
Socio-demographic characteristics were collected in
the online questionnaire (maternal age, marital status,
education, and occupation). Information on a variety
of maternal characteristics was obtained during the
interview; e.g. parity, number of pregnancies with HG,
risk factors, and time since the selected HG pregnancy.
Pre-existing conditions/comorbidity was collected in
the online questionnaire.
HG symptoms and severity
During the interview, women were asked several
detailed questions about the time course and severity
of HG symptoms, including weight loss, ketonuria,
dehydration and/or electrolyte imbalance, and hospital
admissions, due to HG.
Pharmacological treatment and management
A range of questions about HG treatment were pre-
sented, including: use of antiemetic medications or
other therapy for HG, e.g. complementary and alterna-
tive therapy (CAM); treatment of reflux comorbidity;
the effectiveness of HG treatment (classified as none,
moderate, or good); medication adherence; and treat-
ment in the primary and/or secondary health-
care system.
Several questions about healthcare professionals’
attitudes and support were raised. For example, we
asked whether women felt that they had been taken
seriously; their satisfaction with the medical treatment
provided; trust in their healthcare professionals; and
whether they felt optimally cared for and understood
by healthcare professionals. Moreover, each woman
was asked about the level of knowledge her health-
care professionals had about HG. Answers were cate-
gorized as presented in Appendix Table 2. Women
were also asked an open-ended question about what
advice they would give healthcare professionals, based
on their own HG experience.
Impact on daily activities and psychosocial
consequences
Information was collected regarding the consequences
and impact of HG on emotional well-being, social
functioning, daily activities, and sick leave. Each
woman was specifically asked about whether HG had
an impact on her plan for future pregnancies and
whether she had thoughts about or carried out an
elective abortion due to HG. The women were also
asked to score their general well-being during the
selected pregnancy on a scale from zero (the worst
possible imaginable) to ten (as good as she had felt
before the start of pregnancy). The remaining data
were categorized as presented in Table 3.
Data analysis and extraction
Descriptive statistics were utilized as appropriate.
Continuous variables were compared with the non-
parametric Wilcoxon rank-sum test. A p-value of less
than 0.05 was considered significant. All statistical
analyses were performed with the Data Analysis and
Statistical Software, Stata/MP version 14.
Data extracting of the open-ended questions and
the selection of representative statements in Table 4
was done by three of the authors (GCH, BT, MLD).
Ethics
The study was approved by the Regional Committee
for Medical and Health Research Ethics, Region West,
in Norway (2014/1065/REK Vest). All data were
handled confidentially and stored anonymously.
Contact information and study data were stored
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separately. The contact information was deleted after
data collection was completed.
Results
A total of 210 women consented to participate in the
study, and 153 interviews were performed. The inter-
views lasted an average of 48 minutes, ranging from
25 to 120 minutes. Of these, 107 women met the
inclusion criteria and were included in the final study
sample, and 96 women (89.7%) completed the online
questionnaire. A flowchart outlining the patient inclu-
sions and exclusions that led to the final study sample
is depicted in Appendix Figure 1. The average age of
study participants was 30.5 ± 4.5 years. Participants
were mostly married, cohabiting, or in a relationship
(92/96, 95.8%), had a university or college education
(60/96, 62.5%), and were not pregnant (76/107, 71.0%)
at the time of study inclusion (Appendix Table 1).
Nearly 3 out of 4 women (77/107, 72.0%) had experi-
enced hyperemesis gravidarum (HG) during the year
prior to the study. Thirteen women with more than
one HG pregnancy chose to focus on their first experi-
ence with HG.
HG symptoms and severity
Symptoms of nausea arose, on average, in gestational
week (GW) 5 (mean GW: 5.2 ± 1.2 weeks), and the
majority (n = 98/107, 91.6%) had experienced nausea
by GW 6. Fifty-four women (54/105, 51.4%) experi-
enced nausea throughout the entire pregnancy. The
majority of these women (40/54, 74.1%), however,
experienced improvement in the intensity of nausea
as the pregnancy proceeded. Seventy-three women
(73/96, 76.0%) reported that severe nausea symptoms
persisted throughout the entire day (24 h), and 29/107
(27.1%) women could not eat or drink anything when
HG symptoms were most intense. Women that lost
weight due to HG (101/107, 94.4%), on average, lost
9.9% ± 5.5% (range: 0–25%) of their pre-pregnancy
body weight. Seventy-seven (77/107, 72.0%) women
were hospitalized due to HG for an average of 14 ±
18 days (median: 7, range: 1–105 days). Table 1 gives
an overview of the HG characteristics in the
study sample.
Pharmacological treatment and management
of HG
In total, 90.7% of women reported that they had used
at least one antiemetic medication. The most common
medications were metoclopramide (71.0%) and meclo-
zine (51.4%) (Table 2). Symptoms of nausea arose early
in pregnancy, but pharmacological treatment was gen-
erally initiated later in pregnancy (Table 2). Treatment
durations were significantly shorter among women
that reported no efficacy compared to women that
reported good efficacy (metoclopramide: median 4 vs.
56 days, z = 6.00, p < .001; meclozine: median 7 vs.
56 days, z = 4.95, p < .001; and prochlorperazine:
median 2 vs. 22 days, z = 2.14, p = .032).
The interview revealed that the women felt con-
fused about medication regimens. Several women
reported that they discontinued treatment after using
a few tablets without efficacy, and 11.4% of partici-
pants (12/105) did not adhere to the physicians’ pre-
scription. Specific reasons for poor adherence were a
perceived fear of teratogenicity and fear after reading
the patient information leaflet.
In addition to medications, 87.9% (94/107) of
women used one or more CAMs. Of these, only 12.8%
(12/94) reported a positive effect on HG. Heartburn
and acid reflux were common (73/96, 76.0%) among
the study participants. However, only 24.7% (18/73)
used medications for these indications. All women









5% weight loss 90 (84.1)
Two or three HG clinical criteria 90 (84.1)
All three HG clinical criteria 63 (58.9)
HG diagnosis, unspecified clinical symptoms 5 (4.7)
Admitted to the hospital due to HG
Yes 77 (72.0)
No 29 (27.1)
Missing data 1 (0.9)





Missing data 1 (0.9)




Number of pregnancies with HG
Only one 50 (46.7)
More than one 57 (53.3)
Family members with HG
Yes 29 (27.1)
No 78 (72.9)
Data obtained from the interview.
aIncludes meclozine, metoclopramide, ondansetron, prochlorperazine, or
chlorpromazine, which were specifically ask for.
bCAM: complementary and alternative medicines, including acupuncture,
acupressure, ginger, peppermint, and/or homeopathy.
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that received intravenous fluid therapy (n = 81)
reported that it had a positive effect on HG. Two
women received gastric tube feeding after admission
to the hospital.
In the interviews, 22 of 107 (20.6%) women reported
that they were dissatisfied with their pharmacological
treatment for HG. The remaining women (85/107,
79.4%) were satisfied to varying degrees. Twenty
women (18.7%) changed their GPs because they were
not satisfied with the treatment they had received for
HG. Fifty-five women (51.4%) and 42 women (51.2%)
felt that their GPs and midwives respectively had no
knowledge about HG. The study participants felt, in
general, better cared for and understood by hospital
physicians than with their GPs (Appendix Table 2).
Thirty-eight women (35.5%) said specifically that they
were afraid that they would not be believed or taken
seriously before their first contact with the healthcare
system. Nearly half of participants (48/107, 44.9%)
reported that they experienced this after their first
appointment. Many women also reported insensitive, or
even hurtful, remarks from their GPs (Table 4). When
women were asked to give advice to healthcare profes-
sional on how to improve care for patients with HG, the
majority stated “Take us seriously” (71/107, 66.4%).
Impact on daily activities and psychosocial
consequences
All participants reported that HG had had a major
impact on their daily activities and sociability
(Table 3). Several women expressed severe distress
and functional disability caused by HG. In total, 8/107
(7.5%) women reported a history of elective pregnancy
termination due to HG. The experience with HG also
had a profound impact on women’s thoughts about
whether she wanted another child in the future
(Table 3).
Most women (n = 101) had been on sick leave dur-
ing pregnancy due to HG. Among these, 46.5% (47/
101) were absent from work throughout the entire
pregnancy, 28.7% (29/101) were absent from work for
an average of 18.9 ± 5.5 weeks, and the remaining
(25/101, 24.8%) were currently on sick leave or did not
specify sick leave duration. Notably, 55/101 women
(54.5%) had not received any pharmacological treat-
ment for HG before being prescribed sick leave.
The participants described HG as one of the worst
life experiences they had ever had. They used expres-
sions like; “inhuman torture”, “like being nine months
in prison”, “poor self-esteem”, and “the nausea was
much worse than giving birth, I would rather give
birth 10 times instead of having HG”. Selected quota-
tions from women about their experiences with HG
and their satisfaction with the healthcare system are
shown in Table 4.
Discussion
Although a relatively rare condition, HG is a leading
cause of maternal hospitalization during early preg-
nancy. This study revealed several findings of clinical
importance. A striking finding was that the women
describe HG as one of their worst life experiences with
profound morbidity and severe psychosocial
Table 2. Pharmacologic treatment of hyperemesis gravidarum and effects.
Number of patients;
Total ¼ 107 Treatment initiation, GW
Efficacy
None Moderate Good
n (%)a Median ± SD n (%) n (%) n (%)
Metoclopramide 76 (71.0) 8.0 ± 2.8
Continuous 31 (40.8) 8 (25.8) 4 (12.9) 19 (61.3)
As needed 43 (56.6) 21 (48.8) 4 (9.3) 18 (41.9)
Meclozine 55 (51.4) 7.0 ± 3.4
Continuous 26 (47.3) 9 (34.6) 5 (19.2) 12 (46.2)
As needed 29 (52.7) 22 (75.9) 1 (3.4) 6 (20.7)
Ondansetron 31 (29.0) 12.0 ± 5.0
Continuous 14 (45.2) 1 (7.1) 1 (7.1) 12 (85.7)
As needed 14 (45.2) 4 (28.6) 2 (14.3) 8 (57.1)
Promethazine 28 (26.2) 10.0 ± 5.3
Continuous 9 (32.1) 2 (22.2) 5 (55.6) 2 (22.2)
As needed 17 (60.7) 9 (52.9) 6 (35.3) 2 (11.8)
Prochlorperazine 12 (11.2) 9.5 ± 2.9
Continuous 4 (33.3) 0 (0.0) 2 (50.0) 2 (50.0)
As needed 7 (58.3) 4 (57.1) 2 (28.6) 1 (14.3)
Chlorpromazine 11 (10.3) 9.0 ± 7.6
Continuous 2 (18.2) 0 (0.0) 1 (50.0) 1 (50.0)
As needed 6 (54.5) 2 (33.3) 3 (50.0) 1 (16.7)
Data obtained from the interview. GW: gestational week; SD: standard deviation.
aTotal numbers do not add up for the resepective medications, due to missing values for metoclopramide (n = 2), ondanse-
tron (n = 3), promethazine (n = 2), prochlorperazine (n = 1), and chlorpromazine (n = 3).
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Table 3. Negative impacts of hyperemesis gravidarum on daily activities and psychosocial burden on the study participants
while experiencing HG.
Psychosocial burden Number of women, n (%) Daily activities Number of women, n (%)
Feeling depresseda Performing household choresa
Always/most of the time/often 80 (83.3) No impact 0 (0.0)
Sometimes 12 (12.5) Minor impact 0 (0.0)
Rarely/never 4 (4.2) Major impact 96 (100.0)
Reduced quality of lifea Social lifea
Always/often 90 (93.8) No impact 0 (0.0)
Sometimes 6 (6.3) Minor impact 0 (0.0)
Rarely/never 0 (0.0) Major impact 96 (100.0)
Thoughts of elective pregnancy terminationb Relationship with partnera
Yes, always/often 12 (11.2) No impact 16 (17.4)
Yes, sometimes 24 (22.4) Minor impact 32 (34.8)
Yes, non-specified 5 (4.7) Major impact 44 (47.8)
Never 66 (61.7)
Considering future pregnancies after HG pregnancyb Ability to care for childrena
Yes 48 (44.9) No impact 0 (0.0)
No, due to HG 35 (32.7) Minor impact 4 (7.3)
No, due to other reasons 11 (10.3) Major impact 51 (92.7)
Unsure 13 (12.1)
General well-beingb,c Work capacitya
0 39 (36.4) No impact 0 (0.0)
1 24 (22.4) Minor impact 0 (0.0)
2–3 35 (32.7) Major impact 89 (100.0)
4 9 (8.4)
Data obtained from the interview.
aQuestion from the online questionnaire, total n = 96. Numbers do not always add up to 96, because the questions were not relevant for women with-
out a partner (n = 4), without children (n = 41), or without work (n = 7).
bQuestions from interview, n = 107.
cGeneral well-being rated from 0 (= worst possible) to 10 (= as good as pre-pregnancy).
Table 4. A selection of representative quotations from women with HG obtained during the study interviews.
Trivialisation The physician did not take me seriously. I dreaded going there, every time. He told me that pregnancy is not a disease and that
there was no such thing as hyperemesis gravidarum. I felt insignificant.
Woman with 18% weight loss
They all thought that I was exaggerating: psychologists, friends, and family. Nobody understood me.
Woman hospitalized for 5 days, 5% weight lost
I felt that I did finally get help, but it took so long. I told my caregivers that I was not capable of eating and that I lost weight, but
no one took me seriously.
Woman hospitalized for 4 days, 8% weight loss
My midwife believed that HG was nonsense.
Women hospitalized for 5 days, 8% weight loss
The attending physician at the hospital did not understand how it was to have HG. She told me to eat and that I didn’t need to be
hospitalized. I was hurt and felt stupid.
Woman hospitalized for 2 days, 13% weight loss
Medication I did not receive any treatment. I was told not to take any anti-emetic medications. I did not get any advice other than to eat
some crackers.
Woman hospitalized for 7 days, 18% weight loss
I was told to take metoclopramide as needed and no more than necessary. I was also told to pause treatment occasionally.
Woman hospitalized for 2 days, 7% weight loss
Severity I wanted to die, there and then. Absolutely awful. I would lie on the bathroom floor for hours. In the beginning, I tried to stay
hydrated, but I could not retain anything. I was absolutely sensitive to all sound and light. Every move could aggravate the nausea.
Woman hospitalized for 12 days, 14% weight loss
I considered an elective abortion, even though this was a wanted pregnancy that we had planned for a long time.
Women hospitalized for 72 days, 16% weight loss
Healthcare The physician never told me that I had a HG diagnosis. I found out about HG later on, via the Facebook forum. The physician wrote
that I had “extreme nausea in pregnancy”, but never explained to me what it really was.
Woman hospitalized for 25 days, 7% weight loss
I have been in and out of the hospital/emergency room several times. Some physicians were clear about my HG condition, other
physicians told me that I was mentally ill. I switched midwife because she told me that I would be fine after week 10.
Woman hospitalized for 30 days, 10% weight loss
Consequences HG was awful. I wasn’t myself, and I felt guilty because I couldn’t care for my family. It ruined our relationship. I was socially disabled.
Woman with 6% weight loss
I got a new job 3 months before the pregnancy. My co-workers didn’t understand. HG has weakened me. I’m now depressed and
still on sick leave (after birth). I had to quit my job and move to another place.
Women hospitalized for 7 days, 14% weight loss
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consequences. Despite this troubling finding, about
half of the women felt their healthcare professionals
had no knowledge about the condition. Many women
also reported insensitive or even hurtful remarks from
their GPs. As a result of poor experiences, many
women feared the possibility of HG in a future preg-
nancy, and due to this fear, several study participants
did not wish to become pregnant again. This finding
implied that HG had far-reaching consequences for
the woman and her family.
In contrast to NVP, which typically resolves by the
end of the first trimester or during the second trimester
[26,27], half of the women with HG in our study experi-
enced nausea and vomiting throughout the entire
pregnancy, which added extra strain for these women.
Women’s negative experiences were prominent at the
first consultation with the GPs, where nearly half of the
women reported that they were not believed or taken
seriously. In our study, nearly 20% of participants chose
to change GPs, due to unsatisfactory HG management;
in comparison to the general Norwegian population
where about 7.5% switch GPs in 2016 [28]. The majority
of women stated that they wished that healthcare pro-
fessionals would take them more seriously. Other stud-
ies have also reported that patients with HG commonly
wished for empathy, but frequently reported a lack of
support from healthcare professionals and the feeling
that they represented a burden [20,25].
We acknowledge the challenging situation GPs are
in, especially since there are few high-quality studies
assessing the effectiveness of antiemetics for HG
[29,30], and that the illness may progress over time.
However, our study showed that there is room for
improvements in the use of antiemetics and HG man-
agement. Several authors have pointed out that early
recognition and management of all grades of NVP can
prevent delay in diagnosis of HG and reduce the likeli-
hood of hospital admission [4,9,10]. Therefore, it is of
concern that pharmacologic treatment among women
in our study was generally initiated late, and that
about half of the women were prescribed sick leave
before receiving pharmacologic treatment. Typically,
women were advised to use antiemetics, only when
the symptoms became severe. Our study revealed that
over half of the women took antiemetic medications
as needed, and not regularly, on a daily basis, which
has been recommended for the optimal treatment
effect [31]. Indeed, in our study, a clear tendency of
higher efficacy was observed when medications were
taken continuously, compared to medications taken
intermittently. Furthermore, an unexpected finding
was that more women in our study used
metoclopramide (71.0%) than meclozine (51.4%), the
latter being the first-line choice of antiemetic in
Norway. In addition, the EMA released in 2013 a warn-
ing recommending limiting use of metoclopramide to
maximum 5 days to reduce the risk of neurological
side effects [32]. This finding could indicate that the
warning was not well known among healthcare pro-
fessionals in Norway, or that the benefits of using
metoclopramide were considered to outweigh a pos-
sible risk of extrapyramidal side effects in this severely
affected patient group.
In 1997, Mazzotta et al. reported that both healthcare
professionals and patients with HG were reluctant to use
antiemetics, due to a perception that they carried terato-
genic risk [33]. This was also discussed by Koren and
Levichek in 2002 [34]. This perception might cause a
delay in initiating pharmacotherapy. In prescribing med-
ical treatment during pregnancy, one should always con-
sider benefit versus risk trade-off for both the mother
and the foetus. We found that, in extreme cases, women
felt that the only option were termination of otherwise
wanted pregnancies, due to the severity of their symp-
toms. This finding profoundly illustrates that withholding
treatment could be fatal for the foetus. Disturbingly,
about 2/5 of the women in our study had thoughts of
elective pregnancy termination; moreover, some women
reported a history of elective pregnancy termination,
due to HG. Bearing these findings in mind, the risks of
using antiemetic therapy are lower, by far, than the risks
associated with the untreated condition.
In addition to the fear of teratogenicity, reluctance to
prescribe and use of antiemetic therapy could be due to
a lack of knowledge. This possibility was supported by
the fact that, in our study, half the women felt that their
GP had no knowledge about HG. However, the women’s
perspectives of their healthcare providers’ knowledge
about HG do not necessarily reflect their true know-
ledge. Our results further suggested that, once women
were hospitalized, their chances improved of receiving
the support and treatment they needed. In most coun-
tries, however, antenatal care is provided in primary care
facilities, and GPs must make a referral for a woman to
receive specialist or hospital treatment.
Based on our findings, several recommendations
can be made that may significantly improve care for
patients with HG. First, it is important for healthcare
professionals to acknowledge that symptoms and con-
sequences of NVP can vary dramatically from woman
to woman, from mild NVP to HG. There are validated,
easy-to-use tools available, like the 24-h pregnancy-
unique quantification of emesis scoring system (PUQE-
24) [35], which can aid both the assessment of NVP
36 G. C. HAVNEN ET AL
severity and the effectiveness of management. The
PUQE-24 is validated in a Norwegian setting [36], and
it is also incorporated in the Norwegian guideline for
emesis and hyperemesis gravidarum [37]. We believe
that continuous treatment and frequent monitoring of
symptoms and clinical signs of HG should be consid-
ered standard care. Unfortunately, the 2018 version of
the antenatal care guideline in Norway does neither
address NVP nor HG. Second, pharmacotherapy should
not be withheld or delayed for women with nausea
that is so severe that it impacts her daily life. At the
same time, it is important to discuss the risks and ben-
efits of medications with women; indeed, this discus-
sion could promote patient adherence. Third,
healthcare professionals should assess not only on the
severity of symptoms but also the impact on daily life.
Understanding the burden of HG and patients’ per-
spectives is important; our results should inform NVP
guidelines, NVP management, and future research.
The main strength of this study was the extent of
information collected during the structured interviews.
These personal interviews provided detailed informa-
tion about several aspects of patient perspectives on
HG that would not be attainable in a survey. Although
this study was conducted in one country, we do not
believe that the findings on HG management are lim-
ited to Norway alone. Our clinical impressions and dis-
cussions with healthcare professionals in other
countries also revealed similar attitudes and experien-
ces. Though several prior studies have studied man-
agement and consequences of NVP, we do believe it
is essential to study HG in specific due to its severe
nature and potentially serious consequences of mis-
management of HG on maternal health.
This study had several limitations that should be
taken into consideration. The major limitation was the
fact that most data were collected retrospectively after
HG. Nearly 75% of participants had experienced HG dur-
ing the prior year; however, for 27 women, data were
collected between 1 year and 2 years after the preg-
nancy. These long intervals might have had an impact
on participant recall. Especially, the recall regarding
maternal weight may have affected our study sample as
the 5% weight loss was calculated based on self-
reported pre-pregnancy weight and gestational weight.
Indeed, self-reported pre-pregnancy weight have been
shown to be under-reported [38]. Another limitation was
that we relied on self-reporting of HG diagnosis. Finally,
our cohort of women was self-selected, based on recruit-
ment via social media and the patient organization for
HG. Women with more negative experiences may be
more motivated to share their experiences than other
women with HG. Assessing representativeness of our
study sample is challenging due to lack of national sta-
tistics characterizing women with HG in pregnancy.
However, compared to a prior Norwegian study among
women classified as having HG based on maternal self-
report of hospitalization due to nausea and vomiting
during pregnancy [39], we found that the participants in
our study were more often primiparous. As previous
studies have found that primiparous women are less
willing to use prescription medications during preg-
nancy [40], our estimates of medication use may be an
underrepresentation of the medication use among
women with HG in general. Comparative multinational
studies are urgently needed to assess the management
and consequences of HG across Europe and worldwide.
There may be reasons to believe that the negative expe-
riences and consequences described by the women in
our study could be even more profound in countries
with a poorer welfare system than Norway.
Conclusion
We found that women with HG reported suboptimal
management and a lack of support from healthcare
professionals, despite the severe psychosocial burden
of illness and the high impact on their daily activities.
Greater awareness and knowledge are needed among
healthcare professionals to improve care for patients
with HG. Understanding patient perspectives and
acknowledging the impact of the illness are important
factors for optimal HG management.
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Table 1 Appendix Table 1. Sociodemographic characteristics of the study sample at
the time of the interview/completion of the electronic questionnaire.
Total population
Sociodemographic variables n (%)
Paritya
Primi parity 70 (65.4)









1st trimester 3 (2.8)
2nd trimester 19 (17.8)
3rd trimester 9 (8.4)
Not pregnant 76 (71.0)
Months since suffering of HG, median (range) 9 (0–24)
Marital statusb







Highest level of educationb
Elementary school 6 (6.3)











Total number to not add up due to missing numbers; maternal age = 2 (2.1%), chronical condi-
tions = 3 (3.1%), and ethnicity = 2 (2.1%).
aRespondents of the telephone interview, n = 107.
bRespondents of the electronic questionnaire, n = 96.
cIncluding allergy, asthma, diabetes 1 or 2, epilepsy, coronary heart disease, thyroid diseases,
depression or anxiety, migraine, and/or other (free text entry).
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Appendix Table 2. Ratings of health care professionals’ qualities, from the perspective of women with hyperemesis gravidarum
(HG) during the interviews.
Number of women that gave the indicated ratings, n (%)
General practitioner n¼ 107 Hospital physician n¼ 83a Midwife n¼ 82b
To what extent did your … have knowledge about HG?
Not at all 55 (51.4) 16 (20.0) 42 (51.2)
Some 13 (12.2) 12 (15.0) 15 (18.3)
Great 39 (36.5) 52 (65.0) 25 (30.5)
Unsure 0 (0.0) 3 (0.04) 0 (0.0)
Did you feel optimally cared for and understood by your … ?
Yes, a little 8 (7.5) 0 (0.0) 14 (17.1)
Yes, well 20 (18.7) 33 (39.8) 22 (26.8)
Yes, very well 33 (30.8) 25 (30.1) 24 (29.3)
No 46 (43.0) 25 (30.1) 22 (26.8)
Did you trust your… to manage your HG?
Yes 71 (66.4) 68 (81.9) –
No 36 (33.6) 15 (18.1)
aOnly 83 women were in contact with a hospital physician.
bOnly 82 women were in contact with a midwife. No questions were asked about trust in their midwife.
Appendix Figure 1. Flowchart of women that met the inclusion and exclusion criteria for the final study sample. HG: hyperemesis
gravidarum. Of the 107 women included, 96 (89.7%) completed the online questionnaire.
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